Welcome to US Medical Affairs Cardiopulmonary
Welcome to US Medical Affairs Cardiopulmonary
Start Exploring
Welcome to Bayer’s Medical Affairs Cardiopulmonary Platform
This platform focuses on Pulmonary Arterial Hypertension (PAH) [WHO Group 1] and inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment [WHO Group 4].
Bayer’s history is steeped in cardiovascular care and Bayer continues to develop products that may be of benefit for patients with various cardiovascular challenges.
In the area of Pulmonary Hypertension, scientists at Bayer discovered direct stimulators of soluble guanylate cyclase (sGC). Bayer’s compound riociguat became the first member of this distinct class of medicines and the first drug therapy to be approved in two forms of pulmonary hypertension, including PAH [WHO Group 1], and cases of inoperable, persistent or recurrent CTEPH after surgical treatment [WHO Group 4]. We invite you to explore educational resources and information on this platform.
Follow Us
